New and emerging treatments for schizophrenia: a narrative review of their pharmacology, efficacy and side effect profile relative to established antipsychotics
出版年份 2021 全文链接
标题
New and emerging treatments for schizophrenia: a narrative review of their pharmacology, efficacy and side effect profile relative to established antipsychotics
作者
关键词
Schizophrenia, Antipsychotic, Cariprazine, Brexpiprazole, Lumateperone, Pimavanserin, Roluperidone, Ulotaront, Xanomeline, BI 425809, Brilaroxazine, F17464
出版物
NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS
Volume 132, Issue -, Pages 324-361
出版商
Elsevier BV
发表日期
2021-11-25
DOI
10.1016/j.neubiorev.2021.11.032
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- The clinical significance of duration of untreated psychosis: an umbrella review and random‐effects meta‐analysis
- (2021) Oliver D. Howes et al. World Psychiatry
- The effectiveness and safety of cariprazine in schizophrenia patients with negative symptoms and insufficient effectiveness of previous antipsychotic therapy
- (2021) Elmars Rancans et al. INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY
- Muscarinic Cholinergic Receptor Agonist and Peripheral Antagonist for Schizophrenia
- (2021) Stephen K. Brannan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety and tolerability of lumateperone 42 mg: An open-label antipsychotic switch study in outpatients with stable schizophrenia
- (2021) Christoph U. Correll et al. SCHIZOPHRENIA RESEARCH
- Cardiometabolic Safety of Lumateperone (ITI−007): Post Hoc Analyses of Short-Term Randomized Trials and an Open-Label Long-Term Study in Schizophrenia
- (2021) John B. Edwards et al. CNS SPECTRUMS
- Beyond Dopamine Receptor Antagonism: New Targets for Schizophrenia Treatment and Prevention
- (2021) Felipe V. Gomes et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Positive AMPA receptor modulation in the treatment of neuropsychiatric disorders: A long and winding road
- (2021) Bashkim Kadriu et al. DRUG DISCOVERY TODAY
- Discovery of TAK-041: a Potent and Selective GPR139 Agonist Explored for the Treatment of Negative Symptoms Associated with Schizophrenia
- (2021) Holly A. Reichard et al. JOURNAL OF MEDICINAL CHEMISTRY
- Post hoc analysis of a randomised, placebo-controlled, active-reference 6-week study of brexpiprazole in acute schizophrenia
- (2020) Stephen R. Marder et al. ACTA NEUROPSYCHIATRICA
- Cardiac structure and function in schizophrenia: cardiac magnetic resonance imaging study
- (2020) Emanuele F. Osimo et al. BRITISH JOURNAL OF PSYCHIATRY
- Dopamine and glutamate in schizophrenia: biology, symptoms and treatment
- (2020) Robert A. McCutcheon et al. World Psychiatry
- Efficacy and Safety of Lumateperone for Treatment of Schizophrenia
- (2020) Christoph U. Correll et al. JAMA Psychiatry
- Cariprazine Safety in Adolescents and the Elderly: Analyses of Clinical Study Data
- (2020) Balázs Szatmári et al. Frontiers in Psychiatry
- 185 The Safety and Tolerability of Lumateperone 42 mg for the Treatment of Schizophrenia: A Pooled Analysis of 3 Randomized Placebo-Controlled Trials
- (2020) John M Kane et al. CNS SPECTRUMS
- A Non–D2-Receptor-Binding Drug for the Treatment of Schizophrenia
- (2020) Kenneth S. Koblan et al. NEW ENGLAND JOURNAL OF MEDICINE
- EFFICACY AND SAFETY OF CARIPRAZINE IN ACUTE MANAGEMENT OF PSYCHIATRIC DISORDERS: A META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS
- (2020) Hannah Cooper et al. Psychiatria Danubina
- M208. MEASURES OF COGNITION AND SOCIAL FUNCTIONING IN SCHIZOPHRENIA PATIENTS RECEIVING SEP-363856
- (2020) Snezana Milanovic et al. SCHIZOPHRENIA BULLETIN
- M205. LONG-TERM SAFETY OF LUMATEPERONE (ITI-007): METABOLIC EFFECTS IN A 1-YEAR STUDY
- (2020) Andrew Satlin et al. SCHIZOPHRENIA BULLETIN
- T42. HIGH ADHERENCE TO CURRENT ANTIPSYCHOTIC AND ADJUNCTIVE PIMAVANSERIN IN THE ENHANCE STUDY, A PHASE 3 TRIAL TO EVALUATE THE TREATMENT OF SCHIZOPHRENIA IN PATIENTS WITH AN INADEQUATE RESPONSE TO ANTIPSYCHOTIC TREATMENT
- (2020) Brandon Abbs et al. SCHIZOPHRENIA BULLETIN
- T41. SAFETY PROFILE OF ADJUNCTIVE PIMAVANSERIN IN THE ENHANCE STUDY, A PHASE 3 TRIAL FOR THE POTENTIAL TREATMENT OF SCHIZOPHRENIA IN PATIENTS WITH AN INADEQUATE RESPONSE TO ANTIPSYCHOTIC TREATMENT
- (2020) Dragana Bugarski-Kirola et al. SCHIZOPHRENIA BULLETIN
- Identification of a Serotonin 2A Receptor Subtype of Schizophrenia Spectrum Disorders With Pimavanserin: The Sub-Sero Proof-of-Concept Trial Protocol
- (2020) Olga B. Baltzersen et al. Frontiers in Pharmacology
- Efficacy and safety of brexpiprazole in patients with schizophrenia presenting with severe symptoms: Post-hoc analysis of short- and long-term studies
- (2020) Nicole Meade et al. JOURNAL OF PSYCHOPHARMACOLOGY
- Pharmacology profile of F17464, a dopamine D3 receptor preferential antagonist
- (2020) Cristina Cosi et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Randomized, double-blind, placebo-controlled study of F17464, a preferential D3 antagonist, in the treatment of acute exacerbation of schizophrenia
- (2019) Istvan Bitter et al. NEUROPSYCHOPHARMACOLOGY
- Mitigation of Olanzapine-Induced Weight Gain With Samidorphan, an Opioid Antagonist: A Randomized Double-Blind Phase 2 Study in Patients With Schizophrenia
- (2019) William F. Martin et al. AMERICAN JOURNAL OF PSYCHIATRY
- Heterogeneity of striatal dopamine function in schizophrenia: meta-analysis of variance
- (2019) Stefan P. Brugger et al. BIOLOGICAL PSYCHIATRY
- Novel antipsychotics specificity profile: A clinically oriented review of lurasidone, brexpiprazole, cariprazine and lumateperone
- (2019) Filippo Corponi et al. EUROPEAN NEUROPSYCHOPHARMACOLOGY
- SEP-363856, A NOVEL PSYCHOTROPIC AGENT WITH A UNIQUE, NON-D2 RECEPTOR MECHANISM OF ACTION
- (2019) Nina Dedic et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis
- (2019) Maximilian Huhn et al. LANCET
- Antipsychotics: Mechanisms underlying clinical response and side-effects and novel treatment approaches based on pathophysiology
- (2019) Stephen J. Kaar et al. NEUROPHARMACOLOGY
- Keeping up with the therapeutic advances in schizophrenia: a review of novel and emerging pharmacological entities
- (2019) Amanda Krogmann et al. CNS SPECTRUMS
- Heterogeneity and efficacy of antipsychotic treatment for schizophrenia with or without treatment resistance: a meta-analysis
- (2019) Yuya Mizuno et al. NEUROPSYCHOPHARMACOLOGY
- Binding of the D3-preferring antipsychotic candidate F17464 to dopamine D3 and D2 receptors: a PET study in healthy subjects with [11C]-(+)-PHNO
- (2019) Mark Slifstein et al. PSYCHOPHARMACOLOGY
- Schizophrenia—An Overview
- (2019) Robert A. McCutcheon et al. JAMA Psychiatry
- Evidence-based guidelines for the pharmacological treatment of schizophrenia: Updated recommendations from the British Association for Psychopharmacology
- (2019) Thomas RE Barnes et al. JOURNAL OF PSYCHOPHARMACOLOGY
- The effects of antipsychotic treatment on presynaptic dopamine synthesis capacity in first episode psychosis: a positron emission tomography study.
- (2018) Sameer Jauhar et al. BIOLOGICAL PSYCHIATRY
- Multiple Rising Doses of Oral BI 425809, a GlyT1 Inhibitor, in Young and Elderly Healthy Volunteers: A Randomised, Double-Blind, Phase I Study Investigating Safety and Pharmacokinetics
- (2018) Viktoria Moschetti et al. CLINICAL DRUG INVESTIGATION
- Clinical Pharmacokinetics of Atypical Antipsychotics: An Update
- (2018) Massimo Carlo Mauri et al. CLINICAL PHARMACOKINETICS
- Antipsychotic drugs for patients with schizophrenia and predominant or prominent negative symptoms: a systematic review and meta-analysis
- (2018) Marc Krause et al. EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE
- A Long-Term, Open-Label Study to Evaluate the Safety and Tolerability of Brexpiprazole as Maintenance Treatment in Adults with Schizophrenia
- (2018) Andy Forbes et al. INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY
- Cognitive Effects of MIN-101 in Patients With Schizophrenia and Negative Symptoms
- (2018) Richard S. E. Keefe et al. JOURNAL OF CLINICAL PSYCHIATRY
- Pimavanserin evaluated by the FDA
- (2018) Paul Webster LANCET
- Is psychosis a multisystem disorder? A meta-review of central nervous system, immune, cardiometabolic, and endocrine alterations in first-episode psychosis and perspective on potential models
- (2018) Toby Pillinger et al. MOLECULAR PSYCHIATRY
- Efficacy and safety of brexpiprazole for the treatment of acute schizophrenia in Japan: A 6-week, randomized, double-blind, placebo-controlled study
- (2018) Jun Ishigooka et al. PSYCHIATRY AND CLINICAL NEUROSCIENCES
- Evaluation of the Efficacy, Safety, and Tolerability of BI 409306, a Novel Phosphodiesterase 9 Inhibitor, in Cognitive Impairment in Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled, Phase II Trial
- (2018) David Brown et al. SCHIZOPHRENIA BULLETIN
- F46. LUMATEPERONE (ITI-007): FAVORABLE SAFETY PROFILE IN AN OPEN LABEL SAFETY SWITCHING STUDY FROM STANDARD-OF-CARE ANTIPSYCHOTIC THERAPY IN PATIENTS WITH SCHIZOPHRENIA
- (2018) Robert Davis et al. SCHIZOPHRENIA BULLETIN
- S44. LUMATEPERONE (ITI-007) FOR THE TREATMENT OF SCHIZOPHRENIA: PLACEBO-CONTROLLED CLINICAL TRIALS AND AN OPEN-LABEL SAFETY SWITCHING STUDY
- (2018) Kimberly Vanover et al. SCHIZOPHRENIA BULLETIN
- T48. ANTIPSYCHOTIC EFFICACY OF EVENAMIDE (NW-3509) IS DUE TO MODULATION OF GLUTAMATERGIC DYSREGULATION
- (2018) Ravi Anand et al. SCHIZOPHRENIA BULLETIN
- O7.5. LONG-TERM SAFETY AND TOLERABILITY OF BREXPIPRAZOLE IN PATIENTS WITH SCHIZOPHRENIA
- (2018) Mika Hakala et al. SCHIZOPHRENIA BULLETIN
- Response to concerns over Cantillon et al. dopamine serotonin stabilizer RP5063 clinical trial's design, analyses and findings (SCHRES-D-17-00455) by Ahmed S Aboraya, MD, DrPh
- (2018) Marc Cantillon et al. SCHIZOPHRENIA RESEARCH
- Dopamine D2 receptor occupancy of lumateperone (ITI-007): a Positron Emission Tomography Study in patients with schizophrenia
- (2018) Kimberly E. Vanover et al. NEUROPSYCHOPHARMACOLOGY
- Efficacy of F17464, a new preferential D3 antagonist in a placebo-controlled phase 2 study of patients with an acute exacerbation of schizophrenia
- (2017) I. Bitter et al. EUROPEAN PSYCHIATRY
- F17464 a new antipsychotic with preferential D3 antagonist, 5-HT1A partial agonist properties. Neurochemical studies
- (2017) C. Cosi et al. EUROPEAN PSYCHIATRY
- A phase I, randomized, proof-of-clinical-mechanism study assessing the pharmacokinetics and pharmacodynamics of the oral PDE9A inhibitor BI 409306 in healthy male volunteers
- (2017) Katja Boland et al. HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL
- Safety and tolerability of cariprazine in patients with acute exacerbation of schizophrenia
- (2017) Willie Earley et al. INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY
- Cariprazine specificity profile in the treatment of acute schizophrenia
- (2017) Filippo Corponi et al. INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY
- Global improvement with cariprazine in the treatment of bipolar I disorder and schizophrenia: A pooled post hoc analysis
- (2017) Suresh Durgam et al. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
- Efficacy and Acceptability of Cariprazine in Acute Exacerbation of Schizophrenia
- (2017) Ming-jun Zhao et al. JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY
- Activating and Sedating Adverse Effects of Second-Generation Antipsychotics in the Treatment of Schizophrenia and Major Depressive Disorder
- (2017) Leslie Citrome JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY
- Cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia: a randomised, double-blind, controlled trial
- (2017) György Németh et al. LANCET
- Antipsychotic treatment resistance in first-episode psychosis: prevalence, subtypes and predictors
- (2017) A. Demjaha et al. PSYCHOLOGICAL MEDICINE
- Transformed PANSS Factors Intended to Reduce Pseudospecificity Among Symptom Domains and Enhance Understanding of Symptom Change in Antipsychotic-Treated Patients With Schizophrenia
- (2017) Seth C Hopkins et al. SCHIZOPHRENIA BULLETIN
- 18. Evenamide, a Putative Antipsychotic, Targets Abnormal Electrical Activity and Glutamatergic Abnormalities to Improve Psychotic Symptoms in Patients With Schizophrenia: Results From a Phase II, Placebo-Controlled Trial
- (2017) Ravi Anand et al. SCHIZOPHRENIA BULLETIN
- Defining the Locus of Dopaminergic Dysfunction in Schizophrenia: A Meta-analysis and Test of the Mesolimbic Hypothesis
- (2017) Robert McCutcheon et al. SCHIZOPHRENIA BULLETIN
- Dopamine serotonin stabilizer RP5063: A randomized, double-blind, placebo-controlled multicenter trial of safety and efficacy in exacerbation of schizophrenia or schizoaffective disorder
- (2017) Marc Cantillon et al. SCHIZOPHRENIA RESEARCH
- Brexpiprazole in patients with schizophrenia: overview of short- and long-term phase 3 controlled studies
- (2016) Stephen R. Marder et al. ACTA NEUROPSYCHIATRICA
- ITI-007 for the Treatment of Schizophrenia: A 4-Week Randomized, Double-Blind, Controlled Trial
- (2016) Jeffrey A. Lieberman et al. BIOLOGICAL PSYCHIATRY
- First-in-human study assessing safety, tolerability and pharmacokinetics of BI 409306, a selective phosphodiesterase 9A inhibitor, in healthy males
- (2016) Viktoria Moschetti et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Should psychiatrists be more cautious about the long-term prophylactic use of antipsychotics?
- (2016) Robin M. Murray et al. BRITISH JOURNAL OF PSYCHIATRY
- Tolerability and Safety Profile of Cariprazine in Treating Psychotic Disorders, Bipolar Disorder and Major Depressive Disorder: A Systematic Review with Meta-Analysis of Randomized Controlled Trials
- (2016) Kim S. J. Lao et al. CNS DRUGS
- Pimavanserin: First Global Approval
- (2016) Anthony Markham DRUGS
- The dopamine D3 receptor, a quarter century later
- (2016) Pierre Sokoloff et al. EUROPEAN JOURNAL OF NEUROSCIENCE
- ITI-007 in the treatment of schizophrenia: from novel pharmacology to clinical outcomes
- (2016) Robert E. Davis et al. Expert Review of Neurotherapeutics
- The effect of brexpiprazole (OPC-34712) and aripiprazole in adult patients with acute schizophrenia
- (2016) Leslie Citrome et al. INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY
- Cariprazine in the treatment of schizophrenia
- (2016) Suresh Durgam et al. INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY
- Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015
- (2016) Theo Vos et al. LANCET
- Two distinct patterns of treatment resistance: clinical predictors of treatment resistance in first-episode schizophrenia spectrum psychoses
- (2016) J. Lally et al. PSYCHOLOGICAL MEDICINE
- Overview of short- and long-term tolerability and safety of brexpiprazole in patients with schizophrenia
- (2016) John M. Kane et al. SCHIZOPHRENIA RESEARCH
- Efficacy of brexpiprazole in patients with acute schizophrenia: Review of three randomized, double-blind, placebo-controlled studies
- (2016) Christoph U. Correll et al. SCHIZOPHRENIA RESEARCH
- Long-term cariprazine treatment for the prevention of relapse in patients with schizophrenia: A randomized, double-blind, placebo-controlled trial
- (2016) Suresh Durgam et al. SCHIZOPHRENIA RESEARCH
- Brexpiprazole in patients with schizophrenia: overview of short- and long-term phase 3 controlled studies
- (2016) Stephen R. Marder et al. ACTA NEUROPSYCHIATRICA
- ITI-007 in the treatment of schizophrenia: from novel pharmacology to clinical outcomes
- (2016) Robert E. Davis et al. Expert Review of Neurotherapeutics
- Efficacy and Safety of Brexpiprazole for the Treatment of Acute Schizophrenia: A 6-Week Randomized, Double-Blind, Placebo-Controlled Trial
- (2015) Christoph U. Correll et al. AMERICAN JOURNAL OF PSYCHIATRY
- Cariprazine in Acute Exacerbation of Schizophrenia
- (2015) Suresh Durgam et al. JOURNAL OF CLINICAL PSYCHIATRY
- Efficacy and Safety of Cariprazine in Acute Exacerbation of Schizophrenia
- (2015) John M. Kane et al. JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY
- A multicenter, randomized, double-blind, controlled phase 3 trial of fixed-dose brexpiprazole for the treatment of adults with acute schizophrenia
- (2015) John M. Kane et al. SCHIZOPHRENIA RESEARCH
- Deficits in Prefrontal Cortical and Extrastriatal Dopamine Release in Schizophrenia
- (2015) Mark Slifstein et al. JAMA Psychiatry
- A phase II/III trial of bitopertin monotherapy compared with placebo in patients with an acute exacerbation of schizophrenia – Results from the CandleLyte study
- (2014) D. Bugarski-Kirola et al. EUROPEAN NEUROPSYCHOPHARMACOLOGY
- Schizophrenia
- (2014) Anissa Abi-Dargham JOURNAL OF CLINICAL PSYCHIATRY
- On the Discovery and Development of Pimavanserin: A Novel Drug Candidate for Parkinson’s Psychosis
- (2014) Uli Hacksell et al. NEUROCHEMICAL RESEARCH
- Alterations in the serotonin system in schizophrenia: A systematic review and meta-analysis of postmortem and molecular imaging studies
- (2014) Sudhakar Selvaraj et al. NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS
- Functional profile of a novel modulator of serotonin, dopamine, and glutamate neurotransmission
- (2014) Gretchen L. Snyder et al. PSYCHOPHARMACOLOGY
- An evaluation of the safety and efficacy of cariprazine in patients with acute exacerbation of schizophrenia: A phase II, randomized clinical trial
- (2014) Suresh Durgam et al. SCHIZOPHRENIA RESEARCH
- PDE9A is expressed in the inner retina and contributes to the normal shape of the photopic ERG waveform
- (2014) Anuradha Dhingra et al. Frontiers in Molecular Neuroscience
- Cariprazine: chemistry, pharmacodynamics, pharmacokinetics, and metabolism, clinical efficacy, safety, and tolerability
- (2013) Leslie Citrome Expert Opinion on Drug Metabolism & Toxicology
- Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis
- (2013) Stefan Leucht et al. LANCET
- Schizophrenia: an integrated sociodevelopmental-cognitive model
- (2013) Oliver D Howes et al. LANCET
- Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial
- (2013) Jeffrey Cummings et al. LANCET
- Profile of blonanserin for the treatment of schizophrenia
- (2013) Tomomi Tenjin et al. Neuropsychiatric Disease and Treatment
- Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010
- (2012) Christopher J L Murray et al. LANCET
- In vitro pharmacology of aripiprazole, its metabolite and experimental dopamine partial agonists at human dopamine D2 and D3 receptors
- (2011) Yoshihiro Tadori et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Serotonin 2A receptor antagonists for treatment of schizophrenia
- (2011) Bjørn H Ebdrup et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- TAAR1 activation modulates monoaminergic neurotransmission, preventing hyperdopaminergic and hypoglutamatergic activity
- (2011) F. G. Revel et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Cariprazine (RGH-188), a Dopamine D3 Receptor-Preferring, D3/D2 Dopamine Receptor Antagonist-Partial Agonist Antipsychotic Candidate: In Vitro and Neurochemical Profile
- (2010) B. Kiss et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Phosphodiesterase 10A Inhibitor Activity in Preclinical Models of the Positive, Cognitive, and Negative Symptoms of Schizophrenia
- (2009) S. M. Grauer et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Pimavanserin, a Serotonin2A Receptor Inverse Agonist, for the Treatment of Parkinson's Disease Psychosis
- (2009) Herbert Y Meltzer et al. NEUROPSYCHOPHARMACOLOGY
- Selective Muscarinic Receptor Agonist Xanomeline as a Novel Treatment Approach for Schizophrenia
- (2008) Anantha Shekhar et al. AMERICAN JOURNAL OF PSYCHIATRY
- Pimavanserin tartrate: a 5-HT2A inverse agonist with potential for treating various neuropsychiatric disorders
- (2008) Atheir Abbas et al. EXPERT OPINION ON PHARMACOTHERAPY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More